Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients

Table 3 Bivariate and multivariate analysis of risk factors associated with a virological outcome of HIV-1 RNA <50 copies/mL at week 48 of antiretroviral treatment

Risk factor	Bivariate			Multivariate
Risk factor	OR unadjusted	95 % CI	P	OR adjusted	95 % CI	P
Male gender	1.14	0.39–3.32	0.803
Age >40 years	0.35	0.14–0.88	0.023	0.28	0.10–0.78	0.015
Duration of ART >14 years	0.69	0.31–1.50	0.350
Number of previous regimens ≥6	0.97	0.36–2.62	0.963
Baseline HIV-1 RNA >100,000 copies/mL	2.84	1.13–7–13	0.023	2.10	0.74–5.90	0.158
Baseline CD4+ cell count <200 cells/μL	2.72	1.22–6–06	0.012	2.79	1.11–6.97	0.028
Number of mutations to DRV ≥2	0.922	0.41–2.04	0.842
GSS in OBR <1 vs. ≥1	1.028	0.97–1.08	0.308
GSS in OBR ≤1 vs. >1	1.820	0.56–5.91	0.235
GSS in OBR <2 vs. ≥2	0.863	0.38–1.93	0.721
TDF in regimen	1.48	0.64–3.40	0.236
MVC in regimen	0.64	0.16–2.49	0.521
ENF in regimen	2.99	0.93–9.64	0.057
ETV in regimen	0.790	0.32–1.92	0.603
RAL in regimen	0.28	0.09–0.88	0.023	0.37	0.10–0.97	0.046

DRV darunavir, ENF enfuvirtide, ETV etravirine, GSS genotypic susceptibility score, MVC maraviroc, PI protease inhibitor, RAL raltegravir, RAM resistance-associated mutation, TDF tenofovir

ISSN: 1742-6405